key: cord-0754004-q8789joi
authors: Corvol, Harriet; de Miranda, Sandra; Dehillotte, Clémence; Lemonnier, Lydie; Chiron, Raphael; Danner-Boucher, Isabelle; Hamidfar, Rebecca; Houdouin, Véronique; Macey, Julie; Marguet, Christophe; Murris-Espin, Marlène; Reynaud, Quitterie; Reix, Philippe; Gaubert, Martine Reynaud; Kemgang, Astrid; Burgel, Pierre-Régis
title: Cumulative Incidence and Risk Factors for Severe COVID-19 in French People with Cystic Fibrosis
date: 2022-04-27
journal: Clin Infect Dis
DOI: 10.1093/cid/ciac333
sha: 0829de923bf1c412b2205685d08949db575d1bef
doc_id: 754004
cord_uid: q8789joi

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are closely monitored in people with cystic fibrosis (pwCF), with a special emphasis on severe cases. Previous studies used hospitalization rates as proxy for severity. METHODS: We evaluated data from coronavirus disease 2019 (COVID-19) cases diagnosed in French pwCF followed in one of the 47 French CF center over the first year of the pandemic. OBJECTIVE: criteria were applied for defining severity (e.g., respiratory failure and/or death). Data were compared to those from all French pwCF using the French CF Registry. RESULTS: As of April 30, 2021, 223 pwCF were diagnosed with COVID-19, with higher risks in adults (≥18 years, odds ratio [OR] = 2.52, 95% confidence interval [CI] = 1.82-3.48) and post-transplant individuals (OR = 2.68, 95% CI = 1.98-3.63). Sixty (26.9%) patients were hospitalized, with an increased risk in post-transplant individuals (OR = 4.74, 95% CI = 2.49-9.02). In 34 (15%) cases, COVID-19 was considered severe; 28/60 (46.7%) hospitalizations occurred in patients without objective criteria of severity. Severe cases occurred mostly in adults (85.3%) and post-transplant pwCF (61.8%, OR = 6.02, 95% CI = 2.77-13.06). In non-transplanted pwCF, risk factors for severity included low lung function (median ppFEV(1) 54.6% vs. 75.1%, OR = 1.04, 95% CI = 1.01-1.08) and CF-associated diabetes (OR = 3.26, 95% CI = 1.02-10.4). While most cases recovered without sequelae (n = 204, 91.5%), 16 (13%) were followed for possible sequelae, and three post-transplant females died. CONCLUSIONS: Severe COVID-19 cases occurred infrequently during the first year of the pandemic in French pwCF. Non-transplanted adults with severe respiratory disease or diabetes and post-transplant individuals were at risk for severe COVID-19. Thus, specific preventive measures should be proposed.

as at least 90,000 people worldwide. Lung disease remains the major cause of morbidity and 7 mortality in people with CF (pwCF), with a progressive decline in lung function due to a 8 vicious self-perpetuating cycle of airway infections and inflammation [3, 4] . Among the 9 pathogens infecting the airways in pwCF, viruses contribute substantially to the deterioration 10 of respiratory function [5] .

Given the serious respiratory complications caused by viral infections, pwCF are expected to 12 have higher risk of severe COVID-19. As such, the impact of SARS-CoV-2 infections on 13 pwCF have been closely monitored worldwide via national and international consortia [6] [7] [8] [9] [10] [11] [12] .

14 In France, a prospective observational study involving all 47 CF centers has been ongoing 15 since March 2020, with the primary objective of describing the clinical expression of 16 COVID-19 in French pwCF and identifying factors associated with severe outcomes. 17 Previous studies have revealed that post-lung transplant pwCF are at an increased risk of 18 developing severe . However, severity status has been largely examined 19 using healthcare utilization data. Some of the few studies conducted thus far have defined 20 patients with severe COVID-19 based on hospitalization data only. However, indications for 21 hospitalization may differ among countries due to differences across healthcare systems. 22 Moreover, clinical experience suggests that hospitalization practices have evolved since the 23 beginning of the pandemic due to evolving knowledge regarding the management of 19. In the present study, our goal was to present data on all French pwCF diagnosed with 25 A C C E P T E D M A N U S C R I P T COVID-19 using criteria associated with disease severity rather than with only healthcare 1 utilization. These criteria included hospitalization in intensive care unit (ICU), respiratory 2 support, severe complications (respiratory as well as non-respiratory) or death.

Since the first wave of COVID-19 in France in March 2020, all 47 CF centers (which follow 5 over 95% of the 7,500 French pwCF) have been collaborating in conducting a prospective 6 observational study (MR004-2218155) French laws for observational studies, the requirement for written informed consent was hemoptysis, pneumothorax), severe other complications (myocarditis, encephalopathy, renal 10 failure, sepsis, multi-organ dysfunction failure), or death.

Continuous data were expressed as medians and range values, while categorical data were 12 expressed as numbers and proportions (%). Descriptive statistics were presented for all the 13 study variables. We used Fisher's exact test to compare categorical and qualitative data and 14 implemented Mann Whitney's non-parametric test to evaluate continuous variables. A P-15 value of less than 5% was interpreted as evidence of a statistically significant difference. The 16 analyses were carried out using SAS 9.4 software (Cary, NC, USA). Figure 1A shows the evolution in the number of cases per month according to age (adults, 5 ≥18 years vs. children, ≤17 years), transplant status, and nationwide lockdowns (described in 14 We compared the baseline clinical characteristics of 223 SARS-CoV-2 infected pwCF to 15 those of French pwCF not diagnosed with SARS-CoV-2 using data from the French CF 16 Registry [2]. As shown in Table 1 , COVID-19 CF cases were older than the overall CF (2.6%) (OR = 2.68, 95% CI = 1.98-3.63, p <0.001).

We found differences in patient characteristics consistent with older age and transplant status, 1 including lower lung function, a more frequent occurrence of CF-associated diabetes, and of 2 the use of treatments such as oral corticosteroids, azithromycin, CF transmembrane 3 conductance regulator (CFTR) modulators (more widely available to adolescents and adults 4 than children <12 years), and long-term oxygen therapy. 22 The evolution and treatments of the evaluated cases are described in Table 3 . Sixty (26.9%) The post-transplant cases not only had more frequent hospitalizations, but also more 8 hospitalizations in the ICU, a longer duration of hospitalization, and a more frequent need for 9 respiratory support, additional IV antibiotics, and systemic corticosteroids ( Table 3) . Only 22 The baseline clinical characteristics of the pwCF who developed severe COVID-19 were 23 compared to those of the non-severe group to examine risk factors associated with severity 24 ( Table 4) . Among the non-transplanted pwCFs, patients with severe SARS-CoV-2 infection

had the lowest lung function (median ppFEV 1 = 54.6% for pwCF with severe infection, 1 75.1% for pwCF without severe infection, OR=1.04, 95% CI=1.01-1.08) and had more hypertension.

In this study, the severity of COVID-19 acute care was examined based on markers of 21 clinical severity rather than relying solely on hospitalization rates as a proxy for severity, as The present results confirm our preliminary report within data obtained during the first wave 7 of the COVID-19 pandemic as well as in international studies [6] [7] [8] [9] [10] [11] showing that SARS-8 CoV-2 infections occur infrequently in pwCF (with a cumulative incidence of 3% as of April 9 2021). A recent systematic review showed that the risk of developing a SARS-CoV-2 10 infection was not increased in pwCF as compared to the general population, with 339 cases 11 reported among 1,236 pwCF from the European CF Society Patient Registry [17] . Two 12 hypotheses have been proposed to explain these findings: the routine use of hand washing, 13 mask wearing, and physical distancing to prevent human-to-human infection, as well as the 14 younger age of the overall cohort of pwCF as compared to the general population [18] . 15 We observed that children with CF were less likely to be diagnosed with SARS-CoV-2 as 16 compared to adults, a finding comparable to the general population [19] . Only 10% of 17 children with CF and COVID-19 developed severe infections, according to a previous 18 international study conducted during the first wave of the pandemic that showed that children [21, 22] . Children might also seem less likely to be infected because of their 1 higher rates of asymptomatic disease.

Our study confirms that severe cases of COVID-19 occur relatively infrequently in pwCF. randomized clinical trials supporting its prescription, short courses of azithromycin have been 1 widely used in COVID-19 management in the general population due to their 2 immunomodulatory and antiviral properties [32] [33] [34] . We observed that pwCF infected by 3 SARS-CoV-2 were more frequently under azithromycin at the onset of infection than the 4 remaining cohort of French pwCF (51.6% of the cases). This may reflect the older age of 5 these cases (vs. causal etiologies). Nevertheless, these findings contradict the assumption that 6 this treatment might prevent infection. Moreover, this result is consistent with a cross-7 sectional study conducted in Spain in patients treated with long-term macrolides for chronic 8 respiratory disease [35] . Indeed, we found no differences in COVID-19 severity between 9 pwCF never treated with azithromycin and those who received this treatment at some point 10 during the course of their infection.

This prospective study was conducted through the French CF reference network, thus 12 covering all pediatric and adult CF centers and all transplant centers. Additional study 13 strengths are that the standardized study questionnaire was distributed at the start of the 14 pandemic outbreak and that the study was nested within the French CF Registry. The main 15 limitation of this work is that mild cases may have remained undiagnosed due to the absence 16 of sufficient testing for COVID-19. This limitation might not alter our conclusions, as our 17 main results concerned severe cases that would be unlikely to be missed. Another limitation 18 is small number of severe cases of COVID-19, due to their infrequent occurrence, which 19 compelled us to make only univariate associations without possibility of adjustment for 20 confounding factors.

After one year of the COVID-19 pandemic, we found that the cumulative incidence of 23 COVID-19 remained low in pwCF, probably thanks to the fact that pwCF are acclimated to 24 masks, hand hygiene, and social distancing to limit exposure and avoid infection. Non-

transplanted pwCF appear to have better COVID-19 outcomes than anticipated (i.e., as 1 compared to other respiratory viral infections). However, compared to non-transplanted 2 patients, post-transplant pwCF patients were more frequently diagnosed as infected and more 3 likely to develop severe COVID-19. This study highlights the need to pursue preventative 4 strategies, including SARS-CoV-2 vaccinations for pwCF as well as for the general 5 population to protect susceptible patients and decrease viral spread. Finally, as the pandemic 6 is still unresolved and new SARS-CoV-2 variants are arising that may result in differential 7 expression of COVID-19, close monitoring of CF cohorts is necessary to fully understand the 8 consequences of COVID-19 in pwCF. Abbreviations: pwCF, people with cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance 6 regulator; ppFEV 1 , percent predicted forced expiratory volume in 1 s; BMI, body mass index; ABPA, 7 allergic bronchopulmonary aspergillosis. 8 Abbreviations: pwCF, people with cystic fibrosis; CFTR, cystic fibrosis transmembrane 6 conductance regulator; ppFEV 1 , percent predicted forced expiratory volume in 1 s; BMI, 7 body mass index; ABPA, allergic bronchopulmonary aspergillosis. Abbreviations: pwCF, people with cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; ppFEV 1 , percent-predicted forced expiratory 3 volume in 1 s; BMI, body mass index; ABPA, allergic bronchopulmonary aspergillosis. 

Medical ward (non-ICU), n (%)

Hospitalization duration (days), median (range) 10

Exocrine pancreatic insufficiency, n (%)

median (range: min-max) 54.6 (23.3-71.8)